Bioanalysis
Bioanalysis Overview
Whether your focus is on small molecules, proteins, antibodies, vaccines or oligonucleotides, QPS delivers bioanalytical solutions and provides you with a full range of CRO services.
QPS offers four bioanalysis technology platforms:
-
LC-MS/MS for small molecules and polypeptides
-
Ligand Binding Assay (LBA) for proteins, antibodies and vaccines
-
Hybridization-LBA for oligonucleotide-based drugs
-
LC-Radio Flow Detection (RFD) for human and animal mass balance/excretion studies
QPS bioanalysis services support the entire spectrum from early discovery, to IND-enabling ADME, to clinical studies. The ratio of clinical to preclinical studies has averaged approximately 60:40 over the years.
Our bioanalysis function has over 90 technical personnel, as well as more than 20 direct support staff in project and data management, metrology, report writing and sample coordination. This dedicated, skilled and experienced staff ensures that PK drug quantitation studies meet sponsor’s requirements and timelines.
QPS employs state-of-the-art automated equipment for sample preparation and a validated Watson™ LIMS to ensure superior data collection, report accuracy and quick turnaround. In addition to timely, high quality data at competitive prices, QPS provides you with direct access to our technical staff, regularly scheduled updates in a format that works for you and prompt, courteous answers to your inquiries.
QPS also maintains an advanced bioanalytical LC-MS/MS facility in Taipei, Taiwan, offering strategic solutions to Asia-Pacific Rim companies, as well as U.S.-based companies with sites or trials overseas or wishing to complete off-shore studies in Asia. Systems, processes and procedures developed, fine-tuned and field-tested in QPS Delaware are transferred and implemented in QPS Taiwan. Regular cross-training sessions are scheduled between QPS Delaware and QPS Taiwan.
